Skip to main content

Advertisement

SpringerLink
Log in

Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Calcitonin has been reported to reduce acute and chronic back pain in osteoporotic patients. The additive effect of calcitonin with a bisphosphonate on chronic back pain remains unclear. The purpose of this study was to evaluate the effect of combining elcatonin (eel calcitonin) with risedronate for patients with chronic back pain. Forty-five postmenopausal women diagnosed as having osteoporosis with chronic back pain persisting for more than 3 months, after excluding women with fresh vertebral fractures within the last 6 months, were randomly allocated to a risedronate group (risedronate alone, n = 22) and a combined group (risedronate and elcatonin, n = 23). The study period was 6 months. Pain was evaluated with a visual analogue scale (VAS) and the Roland-Morris questionnaire (RDQ). Back extensor strength, bone mineral density, and quality of life on the SF-36 and the Japanese osteoporosis quality of life score were also evaluated. Significant improvements were found in the combined group for VAS at final follow-up compared with baseline and 3 months, mental health status on the SF-36, and JOQOL domains for back pain and general health. The JOQOL domain for back pain improved significantly, but no change was found in the VAS or other domains in the risedronate group. Bone mineral density increased significantly in the two groups, but no significant difference was found between the groups. Back extensor strength did not change in both groups. In conclusion, the use of elcatonin in addition to risedronate for more than 3 months reduced chronic back pain. The additional therapy of risedronate with elcatonin may be a useful and practical choice for the treatment of osteoporosis with chronic back pain persisting more than 3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K (2010) Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 17:209–213

    Article  CAS  PubMed  Google Scholar 

  2. Meschia M, Brincat M, Barbacini P, Crossignani PG, Albisetti W (1993) A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 53:17–20

    Article  CAS  PubMed  Google Scholar 

  3. Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8

    Article  CAS  PubMed  Google Scholar 

  4. Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281–1290

    Article  CAS  PubMed  Google Scholar 

  5. Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 117:549–555

    Article  CAS  PubMed  Google Scholar 

  6. Plosker GL, McTavish D (1996) Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8:378–400

    Article  CAS  PubMed  Google Scholar 

  7. Fujita T, Ohue M, Nakajima M, Fujii Y, Miyauchi A, Takagi Y (2011) Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36. J Bone Miner Metab 29:588–597

    Article  CAS  PubMed  Google Scholar 

  8. Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D (2012) Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 23:17–38

    Article  CAS  PubMed  Google Scholar 

  9. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD004523

  10. Takakuwa M, Iwamoto J (2012) Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. Biol Pharm Bull 35:1159–1165

    Article  CAS  PubMed  Google Scholar 

  11. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  CAS  PubMed  Google Scholar 

  12. Limburg PJ, Sinaki M, Rogers JW, Caskey PE, Pierskalla BK (1991) A useful technique for measurement of back strength in osteoporotic and elderly patients. Mayo Clin Proc 66:39–44

    Article  CAS  PubMed  Google Scholar 

  13. Kumamoto K, Nakamura T, Suzuki T, Gorai I, Fujinawa O, Ohta H, Shiraki M, Yoh K, Fujiwara S, Endo N, Matsumoto T (2010) Validation of the Japanese Osteoporosis Quality of Life Questionnaire. J Bone Miner Metab 28:1–7

    Article  PubMed  Google Scholar 

  14. Miyakoshi N, Itoi E, Kobayashi M, Kodama H (2003) Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis. Osteoporos Int 14:1007–1012

    Article  CAS  PubMed  Google Scholar 

  15. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 49:369–372

    Article  CAS  PubMed  Google Scholar 

  16. Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG (1997) Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 275:112–114

    CAS  PubMed  Google Scholar 

  17. Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A (1999) Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 15:284–289

    Article  CAS  PubMed  Google Scholar 

  18. Abellan Perez M, Bayina Garcia FJ, Calabozo M, Carpintero Benitez P, Figueroa Pedrosa M, Fernandez Crisostomo C, Garcia Lopez A, Garcia Perez S, Mesa Ramos M, Paulino Tevar J et al (1995) Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis. An Med Interna 12:12–16

    CAS  PubMed  Google Scholar 

  19. Wysowski DK, Chang JT (2005) Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165:346–347

    Article  PubMed  Google Scholar 

  20. Nakamura T, Osawa M, Itoh M, Yamaguchi H, Iinuma N, Hayakawa Y, Suzuki H, Kamisaki T, Iwayama S, Nishikawa M (2012) The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study. J Bone Miner Metab 30:715–721

    Article  CAS  PubMed  Google Scholar 

  21. Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150

    Article  CAS  PubMed  Google Scholar 

  22. Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17:273–280

    Article  PubMed  Google Scholar 

  23. Pontiroli AE, Pajetta E, Scaglia L, Rubinacci A, Resmini G, Arrigoni M, Pozza G (1994) Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study. Aging (Milano) 6:459–463

    CAS  Google Scholar 

  24. Papadokostakis G, Damilakis J, Mantzouranis E, Katonis P, Hadjipavlou A (2006) The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. Eur Spine J 15:356–362

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Silverman SL, Azria M (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858–867

    Article  CAS  PubMed  Google Scholar 

  26. Yoshimura M (2000) Analgesic mechanism of calcitonin. J Bone Miner Metab 18:230–233

    Article  CAS  PubMed  Google Scholar 

  27. Ito A, Kumamoto E, Takeda M, Shibata K, Sagai H, Yoshimura M (2000) Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci 20:6302–6308

    CAS  PubMed  Google Scholar 

  28. Ofluoglu D, Akyuz G, Unay O, Kayhan O (2007) The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 26:44–49

    Article  CAS  PubMed  Google Scholar 

  29. Franceschini R, Cataldi A, Barreca T, Salvemini M, Rolandi E (1989) Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin. Eur J Clin Pharmacol 37:341–343

    Article  CAS  PubMed  Google Scholar 

  30. Laurian L, Oberman Z, Graf E, Gilad S, Hoerer E, Simantov R (1986) Calcitonin induced increase in ACTH, beta-endorphin and cortisol secretion. Horm Metab Res 18:268–271

    Article  CAS  PubMed  Google Scholar 

  31. Shah GV, Wang W, Grosvenor CE, Crowley WR (1990) Calcitonin inhibits basal and thyrotropin-releasing hormone-induced release of prolactin from anterior pituitary cells: evidence for a selective action exerted proximal to secretagogue-induced increases in cytosolic Ca2+. Endocrinology 127:621–628

    Article  CAS  PubMed  Google Scholar 

  32. Miyakoshi N, Hongo M, Shimada Y (2012) Prevalence of back pain in postmenopausal osteoporosis and associations with multiple spinal factors. In: Dionyssiotis Y (ed) osteoporosis. InTech, Rijeka, pp 103–114

    Google Scholar 

  33. Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425–434

    Article  CAS  PubMed  Google Scholar 

  34. Itoh S, Sekino Y, Shinomiya K, Takeda S (2013) The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab 31:206–211

    Article  CAS  PubMed  Google Scholar 

  35. van Schoor NM, Smit JH, Twisk JW, Lips P (2005) Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos Int 16:749–756

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Asahi Kasei Co. Ltd (Tokyo, Japan) for providing technical support for this study.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan

    Michio Hongo, Naohisa Miyakoshi, Yuji Kasukawa, Yoshinori Ishikawa & Yoichi Shimada

Authors
  1. Michio Hongo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naohisa Miyakoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuji Kasukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshinori Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoichi Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michio Hongo.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hongo, M., Miyakoshi, N., Kasukawa, Y. et al. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Metab 33, 432–439 (2015). https://doi.org/10.1007/s00774-014-0603-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-014-0603-9

Keywords

Search

Navigation